资金流向方面，鱼跃医疗8月22日主力资金净流出1517.16万元，近五日主力资金净流入1.24亿元。 鱼跃医疗8月22日股价报36.60元，较前一交易日下跌0.25%。盘中最高触及36.73元，最低下探至36.23 元，成交额达4.17亿元。 鱼跃医疗属于医疗器械板块，主营业务涵盖呼吸治疗、血糖管理、急救、家用健康检测等多个领域。公 司是国内家用医疗器械行业的代表性企业，产品线覆盖多个医疗健康细分市场。 公司8月22日发布2025年半年度报告显示，上半年实现营业收入46.59亿元，同比增长8.16%；归母净利 润12.03亿元，同比增长7.37%。公司同时公布中期分红预案，拟每10股派发现金红利2元。分业务板块 来看，血糖管理及POCT解决方案业务增长较快，营收同比增长20%；急救解决方案及其他板块营收同 比增长30.54%。 风险提示：投资有风险，入市需谨慎。本文不构成任何投资建议，投资者应独立判断并承担相应风险。 来源：金融界 ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company's blood glucose business has shown a remarkable growth of 40%, with significant results from overseas expansion, leading to an income increase of over 30% [2] - In 2024, the company reported a revenue of 75.66 billion yuan, a year-on-year decrease of 5.09%, and a net profit attributable to shareholders of 18.06 billion yuan, down 24.63% year-on-year [2] - The company is expected to maintain stable growth in its core sectors, with a focus on enhancing its product matrix and brand influence, particularly in overseas markets [2] - The company is increasing its investment in technology and brand strength, which is anticipated to improve profitability in the long term [2] - Revenue forecasts for 2025-2027 are projected at 86.82 billion, 100.07 billion, and 115.20 billion yuan, with corresponding net profits of 21.11 billion, 24.94 billion, and 29.30 billion yuan, reflecting growth rates of 16.9%, 18.2%, and 17.5% respectively [2] Financial Summary - In 2024, the company achieved a gross margin of 50.14% and a net profit margin of 23.85% [2] - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 2.11 yuan, 2.49 yuan, and 2.92 yuan respectively [3] - The company’s total revenue for 2023 was 79.72 billion yuan, with a year-on-year growth of 12.3% [3] - The net profit attributable to shareholders for 2023 was 2.396 billion yuan, reflecting a year-on-year increase of 50.2% [3]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company's blood glucose business has shown a remarkable growth of 40%, with significant results from overseas expansion, leading to an overall revenue increase of over 30% [2] - In 2024, the company reported a revenue of 7.566 billion yuan, a year-on-year decrease of 5.09%, and a net profit attributable to shareholders of 1.806 billion yuan, down 24.63% year-on-year [2] - The company is expected to maintain stable growth in its core segments, with a focus on enhancing its product matrix and brand influence, particularly in overseas markets [2] Financial Performance Summary - In 2024, the company achieved total revenue of 75.66 billion yuan, with domestic revenue at 65.74 billion yuan (down 8.58% year-on-year) and overseas revenue at 9.49 billion yuan (up 30.42% year-on-year) [2] - The blood glucose management and POCT solutions business generated revenue of 10.30 billion yuan, reflecting a growth of 40.20% [2] - The company’s gross profit margin for 2024 was 50.14%, a decrease of 1.35 percentage points year-on-year, while the net profit margin was 23.85%, down 5.96 percentage points year-on-year [2] Revenue and Profit Forecast - The company is projected to achieve revenues of 86.82 billion yuan, 100.07 billion yuan, and 115.20 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 14.7%, 15.3%, and 15.1% [2] - The net profit attributable to shareholders is expected to be 2.111 billion yuan, 2.494 billion yuan, and 2.930 billion yuan for the same years, with growth rates of 16.9%, 18.2%, and 17.5% [2] - The price-to-earnings ratio (P/E) for 2025 is projected to be 16 times [2]